Blood loss prophylactic associated with higher mortality
Bayer issues a guidance on Trasylol, stating that it should only be used as directed on its label.
Bayer's Trasylol (aprotinin injection) can reduce bleeding in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. However, a new study has found that patients on the treatment also had a higher death rate than patients who received either aminocaproic acid or tranexamic acid. For this reason, Bayer has halted the trial and issued a new guidance to health professionals. The guidance states that Trasylol should be used only according to its labeling. More information can be found on
Recent Videos
Related Content
